Metabolic signatures and predictive biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study

Background: Liposomal doxorubicin hypersensitivity significantly affects breast cancer patients, with widely varying incidence rates (9 % to 46 %). Despite its efficacy, this condition poses a critical barrier to treatment due to the need for precise patient management and the absence of effective p...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xiaorong Su, Yiyin Weng, Yiqi Xiao, Lizhu Weng, Yanbin Zeng, Wanlong Lin, Wei Zhuang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2026-01-01
Edice:	Cancer Treatment and Research Communications
Témata:	Liposomal doxorubicin Hypersensitivity Breast cancer Biomarker Metabolomics
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2468294226000158
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!